News

Contribute towards the global effort to combat antibiotic resistance.

Allecra has one product candidate in Phase 1 clinical trials and another more advanced product candidate in Phase 2 trials. Each of Allecra’s two product candidates is designed to have a unique spectrum of activity and is clearly differentiated from current treatment options and from competitors’ development pipelines

Allecra Therapeutics to present data at 28th European Congress of Clinical Microbiology and Infectious Diseases

Lörrach, Germany and Saint-Louis, France, April 16, 2018 (GLOBE NEWSWIRE)—Allecra Therapeutics (Private), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced six upcoming presentations at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place April 21-24 in Madrid, Spain at the IFEMA-Feria…

Find out more

Allecra Therapeutics announces participation at the H.C. Wainwright annual global life sciences conference in Monte Carlo, Monaco on April 8-10,2018

Lörrach, Germany and Saint Louis, France, April 3, 2018– Therapeutics (Private), today announced it will be featured as a presenting company at the H. C. Wainwright Annual Global Life Sciences Conference. The conference is being held on April 8-10 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. Nicholas Benedict, co-founder and chief…

Find out more

Allecra Therapeutics Announces Positive Top-Line Results from Phase 2 CACTUS Study of its Lead Candidate, AAI101, in Combination with Cefepime to treat complicated Urinary Tract Infections (cUTI)

Target dose established for combination of cefepime/AAI101 with favorable safety and tolerability observed Further efficacy data generated against drug-resistant bacteria Allecra to progress to pivotal Phase 3 registration study during 2018 Lörrach, Germany and Saint Louis, France– – Allecra Therapeutics, a biopharmaceutical company dedicated to the development of novel antibiotics for the treatment of drug…

Find out more

Allecra Therapeutics Announces Fast Track Designation for Lead Antibiotic in Resistant Infections

Supports Allecra’s lead program in Phase 2 clinical trials to treat serious Gramnegative infections Lörrach, Germany and Saint Louis, France– Allecra Therapeutics, a biopharmaceutical company dedicated to the development of novel antibiotics for the treatment of drugresistant bacterial infections, announces today that the U.S Food and Drug Administration (FDA) has granted Fast Track designation for…

Find out more

Allecra Therapeutics Announces New Staged Financing Deal to Take the Company Through to End of Phase 3

Funding supports clinical development up to registration of Allecra’s novel antibiotic to treat resistant Gram-negative bacterial infections in hospitals Lörrach, Germany and Saint Louis, France– Allecra Therapeutics, a biopharmaceutical company dedicated to the development of novel antibiotics forthe treatment of drug-resistant bacterial infections, announces today the initial closing of a staged financing deal designed to…

Find out more

Allecra Announces Initiation of a Phase 2 Clinical Trial for its Novel Antibiotic to Treat Resistant Bacterial Infections

Allecra’s novel β-lactamase inhibitor AAI101, co-administered with the powerful β-lactam cefepime, is to be evaluated in patients for its potential to combat hospital-acquired, resistant Gram-negative infections Lörrach, Germany and Saint Louis, France – Allecra Therapeutics, a biopharmaceutical company dedicated to the development of novel antibiotics to combat drug-resistant bacterial infections, today announces initiation of a…

Find out more

Allecra Therapeutics Strengthens Leadership Team with Appointment of New Chairman and Chief Medical Officer

Lörrach, Germany and Saint Louis, France – Allecra Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of novel antibiotics to combat drug-resistant bacterial infections, announced today two key appointments to significantly strengthen Allecra’s leadership team as the Company enters its next phase of development. Dr. Engelbert (Bert) Tjeenk Willink is appointed to the position…

Find out more

Allecra Therapeutics Announces €22 Million Series B Financing

Funding Supports Phase 2 Development of Novel Antibiotic to Treat Resistant Gram-negative Bacterial Infections in the Hospital Lörrach, Germany and Saint Louis, France – Allecra Therapeutics, a biopharmaceutical company dedicated to the development of novel antibiotics to combat drug-resistant bacterial infections, announced today the closing of its €22 Million Series B investment round. The round…

Find out more
""